Advanced Breast Cancer: Adding Abemaciclib to Fulvestrant Improves Survival

​Updated results from MONARCH 2 report that adding abemaciclib (Verzenio®, Eli Lilly) to fulvestrant (Faslodex®, AstraZeneca) improves overall survival compared with fulvestrant alone in patients with endocrine-refractory hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. "Most patients with metastatic breast cancer have tumors that are HR-positive and are initially treated with endocrine therapy. Although endocrine therapy is an effi...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.